红星资本局10月24日消息 昨日,翰森制药(03692.HK)公告称,公司研发的选择性转染重排RET抑制剂HS-10365胶囊上市申请,已经获得中国药监局受理,该药主要用于RET基因融合阳性的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的治疗。红星资本局注意到,今年已有三款国产RET抗癌药先后获批。资料图三款国产RET抗癌药获批上市RET基因融合是恶性肿瘤的重要驱动因素,临床常见于非小细胞...
Source Link红星资本局10月24日消息 昨日,翰森制药(03692.HK)公告称,公司研发的选择性转染重排RET抑制剂HS-10365胶囊上市申请,已经获得中国药监局受理,该药主要用于RET基因融合阳性的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的治疗。红星资本局注意到,今年已有三款国产RET抗癌药先后获批。资料图三款国产RET抗癌药获批上市RET基因融合是恶性肿瘤的重要驱动因素,临床常见于非小细胞...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.